Top

BMC Endocrine Disorders

Published in:

Open Access 01-12-2021 | Fatty Liver | Research article

Circulating levels of FAM19A5 are inversely associated with subclinical atherosclerosis in non-alcoholic fatty liver disease

Authors: Fatemeh Ali Yari, Parisa Shabani, Sara Karami, Negar Sarmadi, Hossein Poustchi, Ahmad Reza Bandegi

Published in: BMC Endocrine Disorders | Issue 1/2021

Abstract

Background

Family with sequence similarity 19 (chemokine (C-C motif)-like) member A5 (FAM19A5) is a newly identified adipokine. There is a limited number of studies linking FAM19A5 to metabolic disorders. In the current study, we aimed to explore if FAM19A5 is associated with nonalcoholic fatty liver disease (NAFLD). We also sought to determine the possibility of FAM19A5 association with subclinical atherosclerosis in NAFLD patients.

Methods

A total of 69 subjects including 37 NAFLD and 32 control subjects were included in this cross-sectional study. Plasma concentration of FAM19A5 was measured with the ELISA method. Carotid artery intima-media thickness (cIMT) was assessed by the ultrasonography.

Results

Plasma concentration of FAM19A5 in patients with NAFLD was significantly lower in NAFLD patients than controls. Moreover, we observed significant negative correlations between plasma level of FAM19A5 and body mass index (BMI), visceral fat, alanine amino transferase (ALT), aspartate amino transferase (AST), liver stiffness (LS), and cIMT. Following stepwise multiple linear regression analysis, ALT and cIMT were the only determinants of FAM19A5 level.

Conclusions

This is the first report to describe association of circulating FAM19A5 levels with NAFLD. Our findings provide further evidence showing relation of FAM19A5 with the risk of atherosclerosis. However, more studies are necessary to unravel the contribution of lower FAM19A5 levels to the NAFLD pathogenesis and the higher risk of atherosclerosis in these patients.

Iqbal U, Perumpail BJ, Akhtar D, Kim D, Ahmed A. The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease. Medicines. 2019;6(1).

Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. https://doi.org/10.1002/hep.28431.CrossRefPubMed

Ragino YI, Stakhneva EM, Polonskaya YV, Kashtanova EV. The role of secretory activity molecules of visceral adipocytes in abdominal obesity in the development of cardiovascular disease: a review. Biomolecules. 2020;10(3).

Shabani P, Naeimi Khaledi H, Beigy M, Emamgholipour S, Parvaz E, Poustchi H, et al. Circulating level of CTRP1 in patients with nonalcoholic fatty liver disease (NAFLD): is it through insulin resistance? PLoS One. 2015;10(3):e0118650. https://doi.org/10.1371/journal.pone.0118650.CrossRefPubMedPubMedCentral

Shanaki M, Fadaei R, Moradi N, Emamgholipour S, Poustchi H. The circulating CTRP13 in type 2 diabetes and non-alcoholic fatty liver patients. PLoS One. 2016;11(12):e0168082. https://doi.org/10.1371/journal.pone.0168082.CrossRefPubMedPubMedCentral

Shanaki M, Moradi N, Emamgholipour S, Fadaei R, Poustchi H. Lower circulating irisin is associated with nonalcoholic fatty liver disease and type 2 diabetes. Diabetes Metab Syndr. 2017;11(Suppl 1):S467–S72. https://doi.org/10.1016/j.dsx.2017.03.037.CrossRefPubMed

Emamgholipour S, Moradi N, Beigy M, Shabani P, Fadaei R, Poustchi H, et al. The association of circulating levels of complement-C1q TNF-related protein 5 (CTRP5) with nonalcoholic fatty liver disease and type 2 diabetes: a case-control study. Diabetol Metab Syndr. 2015;7(1):108. https://doi.org/10.1186/s13098-015-0099-z.CrossRefPubMedPubMedCentral

Wang Y, Chen D, Zhang Y, Wang P, Zheng C, Zhang S, et al. Novel Adipokine, FAM19A5, inhibits Neointima formation after injury through Sphingosine-1-phosphate receptor 2. Circulation. 2018;138(1):48–63. https://doi.org/10.1161/CIRCULATIONAHA.117.032398.CrossRefPubMed

Lee YB, Hwang HJ, Kim JA, Hwang SY, Roh E, Hong SH, et al. Association of serum FAM19A5 with metabolic and vascular risk factors in human subjects with or without type 2 diabetes. Diab Vasc Dis Res. 2019;16(6):530–8. https://doi.org/10.1177/1479164119860746.CrossRefPubMed

10.

Al Rifai M, Silverman MG, Nasir K, Budoff MJ, Blankstein R, Szklo M, et al. The association of nonalcoholic fatty liver disease, obesity, and metabolic syndrome, with systemic inflammation and subclinical atherosclerosis: the multi-ethnic study of atherosclerosis (MESA). Atherosclerosis. 2015;239(2):629–33. https://doi.org/10.1016/j.atherosclerosis.2015.02.011.CrossRefPubMedPubMedCentral

11.

Zheng J, Zhou Y, Zhang K, Qi Y, An S, Wang S, et al. Association between nonalcoholic fatty liver disease and subclinical atherosclerosis: a cross-sectional study on population over 40 years old. BMC Cardiovasc Disord. 2018;18(1):147. https://doi.org/10.1186/s12872-018-0877-2.CrossRefPubMedPubMedCentral

12.

Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66(6):1138–53. https://doi.org/10.1136/gutjnl-2017-313884.CrossRefPubMed

13.

Ahmadi A, Argulian E, Leipsic J, Newby DE, Narula J. From subclinical atherosclerosis to plaque progression and acute coronary events: JACC state-of-the-art review. J Am Coll Cardiol. 2019;74(12):1608–17. https://doi.org/10.1016/j.jacc.2019.08.012.CrossRefPubMed

14.

Gatto L, Prati F. Subclinical atherosclerosis: how and when to treat it? Eur Heart J Suppl. 2020;22(Suppl E):E87–e90.CrossRef

15.

Singh SS, Pilkerton CS, Shrader CD Jr, Frisbee SJ. Subclinical atherosclerosis, cardiovascular health, and disease risk: is there a case for the cardiovascular health index in the primary prevention population? BMC Public Health. 2018;18(1):429. https://doi.org/10.1186/s12889-018-5263-6.CrossRefPubMedPubMedCentral

16.

Patil R, Sood GK. Non-alcoholic fatty liver disease and cardiovascular risk. World J Gastrointest Pathophysiol. 2017;8(2):51–8. https://doi.org/10.4291/wjgp.v8.i2.51.CrossRefPubMedPubMedCentral

17.

Fadaei R, Meshkani R, Poustchi H, Fallah S, Moradi N, Panahi G, et al. Association of carotid intima media thickness with atherogenic index of plasma, apo B/apo A-I ratio and paraoxonase activity in patients with non-alcoholic fatty liver disease. Arch Physiol Biochem. 2019;125(1):19–24. https://doi.org/10.1080/13813455.2018.1429475.CrossRefPubMed

18.

Kozakova M, Palombo C, Eng MP, Dekker J, Flyvbjerg A, Mitrakou A, et al. Fatty liver index, gamma-glutamyltransferase, and early carotid plaques. Hepatology. 2012;55(5):1406–15. https://doi.org/10.1002/hep.25555.CrossRefPubMed

19.

Targher G, Bertolini L, Padovani R, Zenari L, Zoppini G, Falezza G. Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation. Diabetes Care. 2004;27(10):2498–500. https://doi.org/10.2337/diacare.27.10.2498.CrossRefPubMed

20.

Volzke H, Robinson DM, Kleine V, Deutscher R, Hoffmann W, Ludemann J, et al. Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. World J Gastroenterol. 2005;11(12):1848–53. https://doi.org/10.3748/wjg.v11.i12.1848.CrossRefPubMedPubMedCentral

21.

Maenhaut N, Van de Voorde J. Regulation of vascular tone by adipocytes. BMC Med. 2011;9:25.CrossRef

22.

Han KM, Tae WS, Kim A, Kang Y, Kang W, Kang J, et al. Serum FAM19A5 levels: A novel biomarker for neuroinflammation and neurodegeneration in major depressive disorder. Brain Behav Immun. 2020;87:852–9. https://doi.org/10.1016/j.bbi.2020.03.021.CrossRefPubMed

23.

Huang S, Zheng C, Xie G, Song Z, Wang P, Bai Y, et al. FAM19A5/TAFA5, a novel neurokine, plays a crucial role in depressive-like and spatial memory-related behaviors in mice. Mol Psychiatry. 2020. https://doi.org/10.1038/s41380-020-0720-x.

24.

Kang D, Kim HR, Kim KK, Kim DH, Jeong B, Jin S, et al. Brain-specific chemokine FAM19A5 induces hypothalamic inflammation. Biochem Biophys Res Commun. 2020;523(4):829–34. https://doi.org/10.1016/j.bbrc.2019.12.119.CrossRefPubMed

25.

Lee HL, Seok HY, Ryu HW, Cho EB, Kim BC, Kim BJ, et al. Serum FAM19A5 in neuromyelitis optica spectrum disorders: can it be a new biomarker representing clinical status? Mult Scler. 2019;1352458519885489.

26.

Park MY, Kim HS, Lee M, Park B, Lee HY, Cho EB, et al. FAM19A5, a brain-specific chemokine, inhibits RANKL-induced osteoclast formation through formyl peptide receptor 2. Sci Rep. 2017;7(1):15575. https://doi.org/10.1038/s41598-017-15586-0.CrossRefPubMedPubMedCentral

27.

Merat S, Poustchi H, Hemming K, Jafari E, Radmard AR, Nateghi A, et al. PolyPill for prevention of cardiovascular disease in an urban Iranian population with special focus on nonalcoholic Steatohepatitis: a pragmatic randomized controlled trial within a cohort (PolyIran - liver) - study protocol. Arch Iran Med. 2015;18(8):515–23.PubMed

28.

Inan C, Sayin NC, Gurkan H, Atli E, Gursoy Erzincan S, Uzun I, et al. Schizencephaly accompanied by occipital encephalocele and deletion of chromosome 22q13.32: a case report. Fetal Pediatr Pathol. 2019;38(6):496–502. https://doi.org/10.1080/15513815.2019.1604921.CrossRefPubMed

29.

Shahapal A, Cho EB, Yong HJ, Jeong I, Kwak H, Lee JK, et al. FAM19A5 expression during embryogenesis and in the adult traumatic brain of FAM19A5-LacZ Knock-in mice. Front Neurosci. 2019;13:917. https://doi.org/10.3389/fnins.2019.00917.CrossRefPubMedPubMedCentral

30.

Pan X, Karner CM, Carroll TJ. Myc cooperates with beta-catenin to drive gene expression in nephron progenitor cells. Development. 2017;144(22):4173–82. https://doi.org/10.1242/dev.153700.CrossRefPubMedPubMedCentral

31.

Recinella L, Orlando G, Ferrante C, Chiavaroli A, Brunetti L, Leone S. Adipokines: new potential therapeutic target for obesity and metabolic, rheumatic, and cardiovascular diseases. Front Physiol. 2020;11:578966. https://doi.org/10.3389/fphys.2020.578966.CrossRefPubMedPubMedCentral

32.

Tourniaire F, Romier-Crouzet B, Lee JH, Marcotorchino J, Gouranton E, Salles J, et al. Chemokine expression in inflamed adipose tissue is mainly mediated by NF-κB. PLoS One. 2013;8(6):e66515. https://doi.org/10.1371/journal.pone.0066515.CrossRefPubMedPubMedCentral

33.

Ebrahimi R, Shanaki M, Mohassel Azadi S, Bahiraee A, Radmard AR, Poustchi H, et al. Low level of adiponectin predicts the development of nonalcoholic fatty liver disease: is it irrespective to visceral adiposity index, visceral adipose tissue thickness and other obesity indices? Arch Physiol Biochem. 2019:1–8. https://doi.org/10.1080/13813455.2019.1661496.

34.

Khan UI, Wang D, Sowers MR, Mancuso P, Everson-Rose SA, Scherer PE, et al. Race-ethnic differences in adipokine levels: the study of Women's health across the nation (SWAN). Metabolism. 2012;61(9):1261–9. https://doi.org/10.1016/j.metabol.2012.02.005.CrossRefPubMedPubMedCentral

35.

Bonakdari H, Tardif G, Abram F, Pelletier JP, Martel-Pelletier J. Serum adipokines/related inflammatory factors and ratios as predictors of infrapatellar fat pad volume in osteoarthritis: applying comprehensive machine learning approaches. Sci Rep. 2020;10(1):9993. https://doi.org/10.1038/s41598-020-66330-0.CrossRefPubMedPubMedCentral

36.

Eglit T, Lember M, Ringmets I, Rajasalu T. Gender differences in serum high-molecular-weight adiponectin levels in metabolic syndrome. Eur J Endocrinol. 2013;168(3):385–91. https://doi.org/10.1530/EJE-12-0688.CrossRefPubMed

Title: Circulating levels of FAM19A5 are inversely associated with subclinical atherosclerosis in non-alcoholic fatty liver disease
Authors: Fatemeh Ali Yari
Parisa Shabani
Sara Karami
Negar Sarmadi
Hossein Poustchi
Ahmad Reza Bandegi
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Fatty Liver
Arterial Occlusive Disease
Published in: BMC Endocrine Disorders / Issue 1/2021
Electronic ISSN: 1472-6823
DOI: https://doi.org/10.1186/s12902-021-00820-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Levothyroxine and the risk of adverse pregnancy outcomes in women with subclinical hypothyroidism: a systematic review and meta-analysis

Incidence and prognostic factors of primary thyroid lymphoma and construction of prognostic models for post-chemotherapy and postoperative patients: a population-based study

Does vitamin D supplementation improve ovarian reserve in women with diminished ovarian reserve and vitamin D deficiency: a before-and-after intervention study

Multiple endocrine neoplasia type 1 with a frameshift mutation in its gene accompanied by a giant cervical lipoma and multiple fatty deposits in the pancreas: case report

Insulin resistance and high molecular weight adiponectin in obese and non-obese patients with Polycystic Ovarian Syndrome (PCOS)

A study of correlations between metabolic syndrome factors and osteosarcopenic adiposity

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials